Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

Treatment strategies for newly diagnosed mantle cell lymphoma (MCL) vary substantially according to patient age, performance status, and comorbidities [ 1 ]. Intensive cytarabine-based regimens followed by upfront autologous stem cell transplantation (ASCT) has been preferred for younger or fit patients, while less intensive ones for older or frail patients. Rituximab maintenance therapy is recommended for both groups across major guidelines [ 2 ]. While several large real-world studies have characterized MCL management in Western populations, comparable comprehensive analyses from the Asia-Pacific (APAC) region are limited [ 3 , 4 , 5 , 6 ]. To address this knowledge gap, we conducted a multinational, multicenter retrospective registry study to delineate real-world treatment patterns, evaluate survival outcomes, and assess the impact of upfront ASCT and rituximab maintenance in newly diagnosed MCL patients across the APAC region.